Compare VRTX & PNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTX | PNC |
|---|---|---|
| Founded | 1989 | 1852 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Major Banks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 81.4B |
| IPO Year | 2006 | 2010 |
| Metric | VRTX | PNC |
|---|---|---|
| Price | $444.67 | $221.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 19 |
| Target Price | ★ $539.69 | $237.53 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 05-04-2026 | 04-15-2026 |
| Dividend Yield | N/A | ★ 3.05% |
| EPS Growth | ★ 836.54 | 20.74 |
| EPS | 15.32 | ★ 16.59 |
| Revenue | $2,488,652,000.00 | ★ $23,099,000,000.00 |
| Revenue This Year | $10.81 | $16.47 |
| Revenue Next Year | $10.41 | $4.62 |
| P/E Ratio | $28.74 | ★ $13.46 |
| Revenue Growth | ★ 46.20 | 7.16 |
| 52 Week Low | $362.50 | $148.28 |
| 52 Week High | $510.77 | $243.94 |
| Indicator | VRTX | PNC |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 62.78 |
| Support Level | $427.52 | $199.11 |
| Resistance Level | $467.86 | $227.78 |
| Average True Range (ATR) | 10.92 | 4.23 |
| MACD | 0.45 | 2.35 |
| Stochastic Oscillator | 56.89 | 87.95 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
PNC Financial is one of the three super-regional banks in the US, with around $574 billion in total assets at the end of Dec. 30, 2025. Headquartered in Pittsburgh, Pennsylvania, PNC Financial has a coast-to-coast branch network, with a strong presence in the US Midwest and Northeast. It closed its acquisition of FirstBank in January 2026, which added around $26 billion in assets to its balance sheet, and PNC is currently expanding in the Southern and Western regions of the US. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, asset management, and investment banking. PNC derived around 38% of revenue from fee income and 62% from net interest income in 2025.